SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
Loading market information…
HKSE · 9996.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Peijia Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 48.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Peijia Medical Limited’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Peijia Medical Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$243.01M-64.7% vs estimate |
| Q4 2022 | Mar 31, 2023 | -HK$0.54 | HK$150.38M-69.17% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
HK$1.47-HK$0.08 (-5.16%)
LifeTech Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 38.24% below the high.
HK$18.64-HK$0.58 (-3.02%)
Zylox-Tonbridge Medical Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.43% below the high.
HK$13.15-HK$1.10 (-7.72%)
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.59% below the high.
HK$6.57+HK$0.05 (+0.77%)
Jenscare Scientific Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.16% below the high.
HK$53.20+HK$0.25 (+0.47%)
Shanghai HeartCare Medical Technology Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 20.48% below the high.
HK$0.98HK$0.00 (0.0%)
Venus Medtech (Hangzhou) Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.61% below the high.
HK$0.93-HK$0.04 (-3.63%)
Shanghai Bio-heart Biological Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 89.43% below the high.
